DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
email sent successfully
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
Horizon Therapeutics plc today announced an integrated analysis of efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab will be presented during an oral session at the American College of Rheumatology (ACR) Annual Meeting, Nov. 8-13 in Atlanta. The U.S. Food and Drug Administration is currently evaluating under Priority Review a Biologics License Application (BLA) for teprotumumab in the treatment of active thyroid eye disease (TED). If approved, teprotumumab would be the first FDA-approved medicine for active TED. The Prescription Drug User Fee Act (PDUFA) goal date is March 8, 2020. Teprotumumab is an investigational medicine and its safety and efficacy have not been established.
Oral Presentation: Teprotumumab, A Novel Biologic for Active Thyroid Eye Disease (abstract 1807)
Speaker: Raymond Douglas, MD, PhD, Director of the Orbital and Thyroid Eye Disease Program at Cedars-Sinai Medical Center
Date: Monday, November 4, 2019
Time: 2:45-3:00 PM ET
The event has ended.
Evidence & EducationA Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients With Minimally Active Grav...Context: Radioiodine is an effective an...
People & PlacesJack Ronald Wall, PhDJack Ronald Wall is a Professor of Medic...
Evidence & EducationEnfermedad Ocular Tiroidea¿Qué es la Enfermedad Ocular Tiroidea?...
Videos & VisualsHow to Prepare for an Appointment With a TED Specialisthttps://www.youtube.com/watch?v=sKQo63E2...
Evidence & EducationThyroid Surgery for Graves’ Disease and Graves’ OphthalmopathyBackground: Graves' disease is an autoi...
News & MeetingsIntegrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effect...Horizon Therapeutics plc today announced...
Evidence & EducationHyperthyroid Patients Without Graves’ Orbitopathy are not at Increased Risk of Developing Glaucoma: A Nationwi...Purpose: Graves' disease (GD) and toxic...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.